|
exercise |
8 |
|
fgf21 |
8 |
|
a-fabp |
7 |
|
blood–brain barrier |
7 |
|
ischaemic stroke |
7 |
|
jnk/c-jun signalling |
7 |
|
mmp-9 |
7 |
|
autoimmune hypoglycaemia |
5 |
|
diabetic cardiomyopathy |
5 |
|
diagnosis |
5 |
|
elisa |
5 |
|
insulin receptor autoantibodies |
5 |
|
mitochondrial dysfunction |
5 |
|
sirt3 |
5 |
|
type b insulin resistance |
5 |
|
adipocyte fatty acid binding protein |
4 |
|
antibody drug candidate |
4 |
|
autoimmunity |
4 |
|
diabetes |
4 |
|
endocrinology |
4 |
|
innate immunity |
4 |
|
ischemic stroke |
4 |
|
macrophages |
4 |
|
neutralizing monoclonal antibody 6h2 |
4 |
|
adipokines |
3 |
|
adipose tissue |
3 |
|
fgfr1 |
3 |
|
klb |
3 |
|
metabolic regulation |
3 |
|
obesity |
3 |
|
pparγ |
3 |
|
bile acid |
2 |
|
cerebral ischemia |
2 |
|
cyp7b1 |
2 |
|
farnesoid x receptor |
2 |
|
fatty acid-binding proteins |
2 |
|
hyodeoxycholic acid |
2 |
|
nafld |
2 |
|
parabacteroides distasonis |
2 |
|
pparα |
2 |
